# Novonesis A/S > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/novozymes). ## Overview Novozymes A/S is a Denmark-based biosolutions company that develops industrial enzymes and microbial solutions used to improve performance in manufacturing processes and biological applications. Its products are sold globally across food, agriculture, household care, bioenergy, and other industrial end markets through direct and partner channels. ## Products & services • Industrial enzymes for food, feed, detergents and bioenergy • Microbial solutions and fermentation-based ingredients • Crop and agricultural biosolutions • Ingredient and process optimization services • Application support and technical collaboration - **Industrial enzymes** (45%) — Protein-based catalysts sold into food, detergent, feed, and biofuel processes. - **Microbial solutions** (25%) — Microorganism-based products and fermentation-derived solutions for industrial uses. - **Agricultural biosolutions** (15%) — Biological inputs and crop-related solutions that support farm productivity. - **Application and technical services** (10%) — Formulation support, testing, and customer collaboration around product deployment. - **Other specialty biosolutions** (5%) — Smaller adjacent biological products and tailored solutions for niche uses. - Industrial enzymes for food, feed, detergents and bioenergy - Microbial solutions and fermentation-based ingredients - Crop and agricultural biosolutions - Ingredient and process optimization services - Application support and technical collaboration ## Customers Novozymes sells to industrial customers that use enzymes and microbial solutions inside their own production processes, rather than to end consumers. Its customer base includes food and beverage producers, detergent makers, feed manufacturers, bioenergy operators, and agricultural users who value performance, yield, and sustainability benefits. - **Food and beverage manufacturers** (primary) — Buy enzymes for brewing, baking, dairy, and other processing steps to improve yield and consistency. - **Household and industrial care** (primary) — Buy detergent enzymes and related solutions to improve cleaning performance and formulation efficiency. - **Animal nutrition and feed** (secondary) — Buy enzymes and microbial products that help improve feed conversion and animal performance. - **Bioenergy producers** (secondary) — Buy enzymes that support biomass breakdown and conversion in renewable fuel processes. - **Agricultural users** (secondary) — Buy biological products that support crop health, resilience, and productivity. - Food and beverage manufacturers using enzymes in processing - Detergent companies needing cleaning-performance additives - Feed producers seeking digestive and efficiency improvements - Bioenergy customers using enzymes in biomass conversion - Agriculture customers buying biological crop inputs ## Geography Novozymes operates globally, with sales spread across developed and emerging markets. The business is exposed to regional demand trends, customer manufacturing footprints, and trade or regulatory conditions in the markets where its products are sold and used. - Global sales footprint across North America, Europe, and Asia - Customer demand tied to industrial production in local markets - Exposure to regional regulation in food, agriculture, and chemicals - International operations create currency and supply-chain exposure - Developed and emerging markets both contribute to demand ## Strategy Novozymes focuses on expanding biosolutions adoption across core industrial end markets by improving customer performance, sustainability, and process efficiency. Its strategy depends on innovation, technical customer support, and a broad market reach that allows it to serve multiple industries and geographies. - **Innovation in biosolutions** (medium-term) — Product performance and new applications are central to pricing power and customer retention. - **Broaden market reach** (medium-term) — A diversified customer and geography mix reduces dependence on any one end market. - **Sustainability-enabled use cases** (long-term) — Many customers buy biosolutions to improve resource efficiency and lower environmental impact. - Expand enzyme and microbial adoption across core end markets - Use innovation to improve product performance and differentiation - Deepen technical collaboration with industrial customers - Broaden reach across developed and emerging markets - Support sustainability and process efficiency use cases ## Risks Novozymes is exposed to demand cycles in industrial end markets and to customer concentration in large manufacturing accounts that can change volumes quickly. As a biosolutions company, it also faces technology and competitive risks, regulatory scrutiny in agriculture and industrial uses, and foreign-exchange and cross-border operating exposure. - **End-market demand volatility** [high] — Enzyme and microbial sales depend on customer production volumes in food, detergent, feed, and energy markets. - **Competitive pressure on product performance and pricing** [high] — Customers can switch suppliers if another biosolutions provider offers better economics or performance. - **Regulatory and compliance risk** [medium] — Agricultural and industrial biological products may face approvals, labeling, or usage restrictions. - **Foreign exchange and international operating risk** [medium] — Revenue and costs span multiple currencies and jurisdictions, affecting reported results and execution. - Customer demand can fluctuate with industrial production cycles - Competition can pressure pricing and product differentiation - Regulatory changes can affect agricultural and industrial biosolutions - Global footprint creates currency and trade exposure - Innovation failure can reduce adoption of new products ## Accounting Novozymes’ reported results are shaped by judgement around intangible assets, acquisition-related adjustments, and fair-value estimates tied to biologically derived products and business combinations. As a global manufacturer, it also faces normal accounting sensitivity around foreign exchange translation, inventory valuation, and hedging of cross-border exposures. - **Acquisition accounting** — Affects operating profit and future reported margins - **Goodwill and intangible impairment** — Could create material write-downs if assumptions weaken - **Inventory valuation** — Can affect gross profit through write-downs - **Foreign exchange translation and hedging** — Affects reported revenue, costs, and equity volatility - Acquisition accounting can create amortization and fair-value step-ups - Intangible assets and goodwill require impairment testing - Inventory valuation matters for biological and specialized products - Hedge accounting affects reported foreign-exchange volatility - FX translation impacts consolidated equity and earnings --- *Last updated: 2026-10-24T15:14:43.384117+00:00*